Market Intelligence, Clinical Progress, and High-Purity Reagents for Epitranscriptomics-Targeted Therapeutics.
TarMart Solution Ecosystem & Related Targets
Epitranscriptomic drug discovery demands highly stable, active protein complexes and robust cellular validation tools. TarMart provides a comprehensive suite of sequence-verified reagents designed to accelerate your METTL3 small-molecule inhibitor programs.
"Comprehensive reagent toolkit for METTL3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Complex | METTL3/METTL14 Active Heterodimer Complex / METTL3 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Perfect for HTRF and SPR binding assays. |
View METTL3 Products |
| Gene Delivery | METTL3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View METTL3 Products |
| Benchmark Ab | Anti-METTL3 Recombinant Antibody High-affinity positive control for Western Blot, IP, and ChIP-seq target engagement assays. |
View METTL3 Products |
| Validator | METTL3 siRNA Set Target-specific knockdown verification to confirm phenotype-to-target correlation. |
View METTL3 Products |
| Related Target A | METTL14 Essential obligate partner forming the functional m6A methyltransferase writer complex with METTL3. |
View METTL14 Products |
| Related Target B | FTO Key m6A demethylase (eraser) acting as the functional antagonist to METTL3 in RNA methylation dynamics. |
View FTO Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| In vitro methyltransferase activity requires dimerization | Co-expressed METTL3/METTL14 heterodimer complex ensuring native-like catalytic activity. |
| Selectivity screening against other RNA methyltransferases | Homolog panel including METTL16 and METTL14 available, strictly verified by mass spectrometry. |
| Lack of Controls | Validated target-specific recombinant antibodies and catalytic-inactive mutants included in the catalog. |
| False Positives in Phenotypic Screens | Sequence-verified siRNA pool included for orthologous target knockdown validation. |
Live METTL3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for METTL3 therapeutics is intensifying, with major players shifting focus from academic validation to clinical-stage small molecule inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting combination regimens to overcome resistance and expand efficacy in solid tumors.
METTL3, the catalytic core of the m6A "writer" complex, has emerged as a premier target in epitranscriptomics. Aberrant m6A methylation is strongly linked to oncogene translation, immune evasion, and drug resistance in acute myeloid leukemia (AML) and various solid tumors. Developing highly selective, orally bioavailable small molecule inhibitors represents the dominant therapeutic strategy in this space.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Storm Therapeutics, Accent Therapeutics | AML, Solid Tumors (e.g., CRC, GBM) | Enzymatic Activity & Binding Kinetics (Need highly active METTL3/METTL14 complex) |
| PROTACs / Degraders | Academic consortia, Biotech startups | Refractory Malignancies | Target Ubiquitination & Degradation (Need high-purity tag-labeled METTL3) |
| Combination Therapies | Clinical-stage oncology pipelines | Immune-checkpoint resistant tumors | Synergy Validation (Need stable METTL3 knockdown lentiviral lines) |